Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...

The FDA approved combination dextromethorphan and bupropion extended-release tablets (Auvelity) for adults with major depressive disorder (MDD), Axsome Therapeutics announced on Friday.

Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer ...

Researchers at Zhejiang University, China, have explored mechanisms for the sustained antidepressant effects of ketamine, suggesting that a direct N-methyl-D-aspartate receptor (NMDAR) blockade might ...

AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 AUVELITY ...

Cough-focused biotech Seyltx has secured the option to license a portfolio of eight GluN2B antagonists from NeurOp, including one candidate that has completed a phase 1 trial. The drugs are all ...

Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue. Researchers ...

When it comes to brain proteins, small changes can make a dramatic difference. Researchers studying NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment ...

The links between neurons are crucial to the brain, and brain cells can reorganize the way they are linked together in a phenomenon known as neuroplasticity. This process is ongoing during a lifetime, ...

Scientists have identified a promising target for treatment of a devastating autoimmune disease affecting the brain.